Expert Insights Into Amyloidosis: The Future for Patients with ATTR Cardiac Amyloidosis is Brighter

Описание к видео Expert Insights Into Amyloidosis: The Future for Patients with ATTR Cardiac Amyloidosis is Brighter

The treatment for patients with Transthyretin Cardiac Amyloidosis has advanced significantly since 2018 when there were no FDA-approved therapies. In this presentation, Dr. Mat Maurer from Columbia University shares how diagnostic imaging techniques have significantly improved, thereby reducing the need for an invasive heart biopsy. In addition, he shares fascinating statistics on how the age and stage of diagnosis has been evolving. Based on today’s clinical trials, providers are optimistic that the expansion of options for patient care will continue. The future is indeed looking brighter.

Комментарии

Информация по комментариям в разработке

Похожие видео